Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16715012 | 1.00 | MMP1 (0.37) | MMP1ADAM17KMT2AKCNA5ALDH1A1 | |
| SCHEMBL16611662 | 1.00 | MMP1 (0.37) | MMP1ADAM17KMT2AKCNA5ALDH1A1 | |
| SCHEMBL15208236 | 0.92 | GAA (0.39) | MMP1ADAM17KMT2AALDH1A1MEN1 | |
| SCHEMBL20402405 | 0.92 | GAA (0.39) | MMP1ADAM17KMT2AALDH1A1MEN1 | |
| SCHEMBL14746514 | 0.91 | POLB (0.36) | MMP1ADAM17KCNA5SMN1; SMN2FKBP1A | |
| SCHEMBL15207067 | 0.91 | POLB (0.36) | MMP1ADAM17KCNA5SMN1; SMN2FKBP1A | |
| SCHEMBL15207251 | 0.90 | ALDH1A1 (0.42) | KMT2AALDH1A1MEN1LMNAHTT | |
| SCHEMBL15365099 | 0.90 | MMP1 (0.35) | MMP1ADAM17KCNA5CASP1SMN1; SMN2 | |
| SCHEMBL16611903 | 0.90 | GAA (0.39) | MMP1ADAM17 | |
| SCHEMBL16611901 | 0.90 | GAA (0.39) | MMP1ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331724-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2023-10-19 | — | — | US | disclosed |
| US-11731971-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2023-08-22 | — | — | US | disclosed |
| US-20210371419-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2021-12-02 | — | — | US | disclosed |
| US-9181250-B2 | Beta-lactamase inhibitor and process for preparing the same | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2015-11-10 | — | — | US | disclosed |
| US-20150141401-A1 | NOVEL BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2015-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731971-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | MMP1 196/4885ADAM17 2822/4885KMT2A 4162/4885 |
| US-20150141401-A1 | NOVEL BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | ME1, FN1, FNTB | MMP1 115/4885ADAM17 1006/4885KMT2A 2671/4885 |
| US-20210371419-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | MMP1 196/4885ADAM17 2822/4885KMT2A 4162/4885 |
| US-20230331724-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | MMP1 196/4885ADAM17 2822/4885KMT2A 4162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.